Citius Pharmaceuticals (CTXR) Net Cash Flow (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Net Cash Flow came in at -$3.1 million in Q1 2026, down 191.64% YoY from $3.4 million in Q1 2025, and down 190.26% on a QoQ basis from $3.5 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Net Cash Flow (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Net Cash Flow data on file, last reported at -$3.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 191.64% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (up 148.53% YoY) and the FY2025 annual result came in at $1.0 million, up 104.31% from the prior year.
- Net Cash Flow fell to -$3.1 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $6.1 million in Q2 2025 to a low of -$9.7 million in Q1 2022.
- A 5-year average of -$3.8 million and a median of -$6.1 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow plunged 298.45% — and 2025, when it jumped 261.22%.
- Tracing CTXR's Net Cash Flow over 5 years: stood at -$4.8 million in 2022, then retreated by 27.17% to -$6.1 million in 2023, then jumped by 64.93% to -$2.2 million in 2024, then jumped by 261.22% to $3.5 million in 2025, then tumbled by 190.26% to -$3.1 million in 2026.
- The last three Net Cash Flow figures came in at -$3.1 million (Q1 2026), $3.5 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | Citius Pharmaceuticals | 15.82 Mn | 15.82 Mn | 1.00 Mn | 12.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.13 Mn |
| Mar 31, 2026 | -3.13 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 6.06 Mn |
| Jun 30, 2025 | 6.06 Mn |
| Mar 31, 2025 | -1.07 Mn |
| Mar 31, 2025 | -1.07 Mn |
| Dec 31, 2024 | -2.15 Mn |
| Dec 31, 2024 | -2.15 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Dec 31, 2023 | -6.14 Mn |
| Dec 31, 2023 | -6.14 Mn |